-
The core variety of Yasheng Medicine, HQP1351, was qualified as an FDA orphan drug
Time of Update: 2021-03-03
HQP1351, China's first third-generation BCR-ABL targeted drug-resistant CML treatment, is currently in the critical Phase II clinical trial phase and plans to submit a new drug listing application (NDA) this year.
-
Novaral TQJ230 injections are declared clinically in China
Time of Update: 2021-03-03
January 8, the official website of CDE showed that Novartic's domestic clinical application for TQJ230 injection has been accepted by CDE, a specific targeted lipoprotein (a) elevated antisypolytic
-
Sovantini was awarded two fast-track qualifications by the FDA
Time of Update: 2021-03-03
China Non-Pancreatic Neuroendocrine Tumor Research: In 2015, And Huang Pharmaceuticals launched the SANET-ep study, a Phase 3 clinical trial in China in which Sovantini is adapted to advanced non-pancreatic neuroendocrine tumors, which was announced in June 2019 to reach the primary therapeutic endpoint and terminate the study early.
-
FDA approves Fiasp to treat diabetes in children
Time of Update: 2021-03-03
no and Nord announced today that the U.S. Food and Drug Administration has approved 100 u/ ml of Fiasp (mendon insulin injection) as an insulin option for new meals for children with diabetes.
-
The first clinical study of Redsiway's treatment, New Crown, has been published
Time of Update: 2021-03-03
The study revealed the structural characteristics of the core "engine" of the viral genetic material transcription replication machine, which laid an important foundation for the development of drugs for neo-crown pneumonia.
-
Novar3/Incyte launches jakafi Phase II Covid-19 Phase III clinical trial
Time of Update: 2021-03-03
, Novart and Incyte announced that they will launch the second Phase III clinical trial of JAK inhibitor Jakafi (ruxolitinib) for COVID-19 to evaluate the safety and effectiveness of Jakafi Joint Standard Care (SoC) in patients with acute respiratory distress syndrome (ARDS) COVID-19 that requires mechanical aeration.
-
The study on the treatment of chronic kidney disease iii in Dagle net was successfully terminated early
Time of Update: 2021-03-03
On September 16, 2019, the FDA granted Dagly net fast track eligibility to delay progression in renal failure and prevent cardiovascular and kidney death risk in patients with chronic kidney disease.
-
Applications for clinical trials of Beda Pharmaceuticals' innovative bpi-27336 drug were accepted
Time of Update: 2021-03-03
BPI-28592 belongs to the second generation of TRK inhibitors, preclinical data show that its biological activity in animals is consistent, can effectively inhibit tumor cell proliferation, and can be effective in Lalotrectinib drug-resistant mutations such as TRKA G595R, TRKC G623, it is expected to provide a new molecularly targeted treatment for NTRK mutation tumor patients to provide more benefits.
-
The U.S. Food and Drug Administration has approved a new treatment for triple negative breast cancer
Time of Update: 2021-03-03
, the U.S. Food and Drug Administration has accelerated approval of treatment for adult patients with triple-negative breast cancer that has spread to other parts of the body.
-
Nerlynx's treatment for early breast cancer has been approved in Singapore
Time of Update: 2021-03-03
Data from ExteNET, a Phase III clinical trial, confirmed that Nerlynx significantly reduced the risk of recurrence in patients with HER2 plus early breast cancer, benefiting most from women who were positive for hormone-positive (HR-plus) and who started Nerlynx therapy within 12 months of completing terratin monoantigen-assisted therapy, for which the risk of recurrence was reduced by 42 percent over five years.
-
Lilly Tauvaid (Flortaucipir F18) is approved by the FDA
Time of Update: 2021-03-03
Eli Lilly recently announced that the U.S. Food and Drug Administration (FDA) has approved Tauvid (Flortaucipir F 18 injection) for brain ect electron emission fault scanning (PET) imaging, a radiodiagnostic agent that is evaluating Alzheimer's (AD) adult patients with cognitive impairment to determine the density and distribution of brain aggregation tau nerve fiber tangle (NFT).
-
The key clinical results of Xindili monoantigen were published
Time of Update: 2021-03-03
The ORIENT-2 study, published at asCO's annual meeting, was a randomized, open, multicenter, Phase II controlled clinical study comparing the efficacy and safety of cinnamo monoanti and chemotherapy (yew alcohol or elliptical) in patients with advanced/metastatic esophageal squamous cancer who failed first-line treatment.
-
The combination of the two immunotherapy combinations of Shishi Shiguibao has been approved by the FDA
Time of Update: 2021-03-03
BMS announced that the FDA has approved the PD-1 inhibitor Opdivo (nivolumab), in association with the CTLA-4 inhibitor Yeervoy (ipilimumab), to treat patients with hepatocellular carcinoma (HCC) who have previously received treatment with sorapinib.
-
Merck's Bavencio meets mid-term analysis of bladder cancer
Time of Update: 2021-03-03
New data from the JAVELIN Bladder 100 Phase III study show that bavencio (avelumab) reached the primary endpoint of its overall survival rate (overall survival) in the planned midterm analysis, which was previously untreated for locally advanced or metastatic urethra cancer (UC).
-
Fda approves additional treatments for haemophilia and inhibitors of type A or B in adults and adolescents
Time of Update: 2021-03-03
the safety and effectiveity of Sevenfact was determined by data from a clinical study that assessed 27 patients with type A or b haemophilia using inhibitors, including 465 mild or moderate treatments and three severe bleeding episodes.
-
K drug small cell lung cancer PHASE III clinical reach PFS endpoint miss OS endpoint
Time of Update: 2021-03-03
KEYNOTE-604 was a randomized, double-blind, placebo-controlled Phase III study that recruited 453 SCLC patients who had not yet used system therapy to evaluate the effectiveness of Keytruda combined chemotherapy in patients with newly diagnosed, widespread stage small cell lung cancer compared to chemotherapy.
-
AZ/Merca East Lynparza EU approval is on the fly
Time of Update: 2021-03-03
AstraZeneca and Merck and Co have jointly announced that the European Medicines Agency's (EMA) Commission on Human Pharmaceutical Products (CHMP) has issued an active review recommending approval of
-
Bayer has released the latest clinical data for the treatment of TRK fusion cancer with the targeted drug Vitrakvi
Time of Update: 2021-03-03
Bayer recently released the latest clinical data from the precision oncology drug Vitrakvi, which continues to show high remission rates and duration of remission while maintaining good safety in an extended data set of 116 adult TRK fusion cancer patients, including those with brain metastasis.
-
Key clinical studies of breakthrough drugs for schizophrenia have been successful
Time of Update: 2021-03-03
The results showed that the total score of positive and negative symptoms (PANSS) in the SEP-363856 daily elastic dose (50-75 mg) was statistically and clinically significantly improved compared to the placebo group in week 4 of treatment (-17.2 vs -9.7; p-0.001).
-
Rivalif, a new drug for green leafy drug Alzheimer's disease, has been accepted by the European Union
Time of Update: 2021-03-02
The product was developed by the company's subsidiary, Luye Pharma AG (Green Leaf Germany), on a permeable patch research and development platform for key products for central nervous system diseases.
